Distribution analysis of intraperitoneally administrated nanomicellar drugsin peritoneal metastasis
| Project/Area Number |
24390310
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Partial Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KITAYAMA Joji 東京大学, 医学部附属病院, 准教授 (20251308)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥18,330,000 (Direct Cost: ¥14,100,000、Indirect Cost: ¥4,230,000)
Fiscal Year 2014: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2013: ¥6,630,000 (Direct Cost: ¥5,100,000、Indirect Cost: ¥1,530,000)
Fiscal Year 2012: ¥7,410,000 (Direct Cost: ¥5,700,000、Indirect Cost: ¥1,710,000)
|
|---|
| Keywords | 腹腔内化学療法 / NK105 / ナノ化抗癌剤 / 繊維化 / 血管新生阻害 / 腹膜播種 / CAF / 胃癌 / CD90 / drug delivery / 線維化 / 間葉性幹細胞 / 腹腔 / ナノミセル / パクリタキセル / ミリプラチン / CD326 |
|---|
| Outline of Final Research Achievements |
Intraperitoneal (IP) administration of nanomicellar PTX (NK105) significantly reduced peritoneal tumors than conventional PTX formulation with similar systemic toxic effects, suggesting the clinical usefulness of IP-NK105. Peritoneal nodules are covered with fibrous capsule containing many CD31(+) microvessels both in human and mice. After IP-PTX, however, the peripheral vessels were greatly reduced in number with luminal obstruction. These findings strongly suggest that the remarkable efficacy of IP-PTX is partly dependent on the destruction of peripheral tumor vessels. CD90(+) cells in human peritoneum vigorously grew in culture and express CAF characteristics by TGF-b, and IP co-injection with MKN45 significantly enhanced peritoneal metastasis in nude mice. The CD90(+) cells were engrafted in metastatic nodules mainly at the fibrous area. Oral administration of Dasatinib significantly inhibited the development of peritoneal metastasis of MKN45 with reduced fibrillar formation.
|
Report
(4 results)
Research Products
(43 results)
-
-
-
-
-
-
-
-
-
-
-
-
[Journal Article] Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis.2014
Author(s)
Takahara N, Isayama H, Nakai Y, Sasaki T, Ishigami H, Yamashita H, Yamaguchi H, Hamada T, Uchino R, Mizuno S, Miyabayashi K, Mohri D, Kawakubo K, Kogure H, Yamamoto N, Sasahira N, Hirano K, Ijichi H, Tateishi K, Tada M, Kitayama J, Watanabe T, Koike K.
-
Journal Title
J Gastrointest Cancer.
Volume: 45(3)
Issue: 3
Pages: 307-11
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
-
[Presentation] 腹膜播種を伴う胃癌に対するS-1/オキサリプラチン+パクリタキセル腹腔内投与併用療法2015
Author(s)
上之園 芳一,石神 浩徳,藤原 義之,富田 寿彦,今本 治彦,今野 元博,梨本 篤,藪崎 裕,福島 亮治,小寺 泰弘,今村 和広,上田 修吾,山下 裕玄,山口 博紀,北山 丈二
Organizer
第87回日本胃癌学会総会
Place of Presentation
リーガロイヤルホテル広島（広島市）
Year and Date
2015-03-04 – 2015-03-06
Related Report
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
